-
Truist Securities Raises Price Target on Gilead Sciences, Inc. (GILD) to $145, Keeps Buy Rating
01 Feb 2026 19:08 GMT
… Securities Raises Price Target on Gilead Sciences, Inc. (GILD) to $145, … told investors in a research note that it was revising … also provided an update on Gilead Sciences, Inc. (NASDAQ:GILD). … for the group this year. Gilead Sciences, Inc. (NASDAQ:GILD) is …
-
<![CDATA[NCCN Names Trodelvy a Preferred First-Line Treatment for Metastatic TNBC]]>
05 Feb 2026 02:06 GMT
… than its currently approved indications. Gilead Sciences has submitted supplemental applications to … in Oncology (NCCN Guidelines®),” by Gilead Sciences. News release; Feb. 4, 2026 … more news on cancer updates, research and education, don’t forget …
-
API Manufacturing: Key Trends Reshaping the Global Market
05 Feb 2026 01:41 GMT
… .
In recent months, Sanofi, AstraZeneca, Gilead Sciences, Johnson & Johnson, Takeda, GSK … across the U.S. in research and development and supply chain …
-
The Escalator: Argenx, Gilead Sciences, Bristol Myers Squibb and more
08 Jan 2026 13:42 GMT
… chief medical officer.
Pharma marketing research firm Konovo added Swathi Kulkarni … CEO of Alloy Genetic Medicines.
Gilead Sciences promoted Keeley Wettan to EVP … that will have him overseeing research into adverse childhood experiences.
QBFox …
-
As U.S. Life Sciences Market Recovers, “Definite Dichotomy” Among Companies
04 Feb 2026 17:57 GMT
… , Gilead Sciences is building a 182,000 square-foot research center … $1.364 billion) London research center while AstraZeneca paused … about $273 million) Cambridge research facility. How much do …
In the Bay Area, Gilead Sciences and [Roche subsidiary] Genentech …
-
Gilead Sciences exercises option to license Assembly Biosciences Helicase-Primase Inhibitor programs for recurrent genital herpes
28 Dec 2025 11:19 GMT
Foster City: Gilead Sciences and Assembly Biosciences have announced … by serious viral infections. Our research partnership with Assembly Bio has … Development, Virology Therapeutic Area Head, Gilead Sciences. “Collaborations and partnerships are key …
-
Pharmaceuticals Market to Register a Robust CAGR of 8.19% During the 2026–2034 Forecast Period
04 Feb 2026 13:00 GMT
… therapies, and strong investments in research and development across developed and … .K.)
Amgen Inc. (U.S.)
Gilead Sciences, Inc. (U.S.)
Takeda Pharmaceutical … (Japan)
Get a Free Sample Research Report:
https://www …
-
Gilead Sciences to acquire Repare’s RP-3467
26 Dec 2025 09:46 GMT
Gilead Sciences has signed an agreement to … ’s leading expertise in oncology research and development with RP-3467 …
-
Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration
24 Dec 2025 12:29 GMT
… definitive asset purchase agreement for Gilead Sciences, Inc. to acquire Repare’s … ’s leading expertise in oncology research and development with RP-3467 …
-
Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
22 Dec 2025 14:16 GMT
… by serious viral infections. Our research partnership with Assembly Bio has … from Gilead next year.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company … funding necessary to continue its research activities, clinical studies, and other …
About
© 1995-2026